Compare SIRI & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SIRI | RYTM |
|---|---|---|
| Founded | 2013 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3B | 6.4B |
| IPO Year | 1996 | 2017 |
| Metric | SIRI | RYTM |
|---|---|---|
| Price | $22.70 | $91.12 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 14 |
| Target Price | $25.00 | ★ $129.43 |
| AVG Volume (30 Days) | ★ 5.5M | 757.0K |
| Earning Date | 05-07-2026 | 05-25-2026 |
| Dividend Yield | ★ 4.86% | N/A |
| EPS Growth | ★ 136.32 | 28.34 |
| EPS | ★ 2.23 | N/A |
| Revenue | ★ $5,425,129,000.00 | N/A |
| Revenue This Year | $1.81 | $58.38 |
| Revenue Next Year | $0.65 | $83.95 |
| P/E Ratio | $9.95 | ★ N/A |
| Revenue Growth | ★ 8.13 | N/A |
| 52 Week Low | $18.69 | $45.91 |
| 52 Week High | $25.36 | $122.20 |
| Indicator | SIRI | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 67.49 | 38.01 |
| Support Level | $22.76 | $83.98 |
| Resistance Level | $23.45 | $96.92 |
| Average True Range (ATR) | 0.53 | 5.41 |
| MACD | 0.15 | -0.89 |
| Stochastic Oscillator | 99.52 | 23.76 |
SiriusXM operates almost exclusively in the US through its SiriusXM and Pandora audio services. SiriusXM is primarily a satellite radio service that offers nationwide coverage and mostly ad-free listening, with proprietary channels and exclusive content. It makes agreements with automakers to install its radios in vehicles and give trial services to vehicle buyers, which have traditionally fed its subscriber base. The company provides the service via a fleet of geostationary satellites it owns and operates, and now offers a streaming SiriusXM option. Pandora, which accounts for a much smaller portion of revenue and profit, offers a subscription and ad-supported streaming music service that competes with industry giants such as Spotify, Apple Music, and YouTube Music.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.